TRICHOMONADS ERADICATION IN CYSTIC FIBROSIS-A New THerapeutic Procedure

KRVAVAC S. Public Health Center,Sarajevo,Bosnia-Herzegovina


The immunogenicity and crossimmunity are proved in all three
human Trichomonas(T) species,which colonize urogenital,digestive
and respiratory tracts:T vaginalis,hominis and tenax.Our findings
of T infection of respiratory mucus whith its aflagellary leukocytoid
form,in all 12 randomly recruited Cystic fibrosis (CF) patients
/XIIth Congress Obst/Gyn Rio de Janeiro 1988:691/ and immunity
restoring after T eradication(E) by the immunocompromised patients
/Vth AIDS Conf Montreal 1989;MCP 138/ logically suggest
TE in CF regardless of relation between respiratory T infection and
CF /Postgrad Med J 1990;62;156/.
As these protozoa are strong immunodepressive agents,E can result in
significant disburdening of immune apparatus in CF patients.Moreover,
T transports and even protects other agents (viruses,Escherichia,
Pseudomonas, Helicobacter, probably even mycobacteria and treponema)
 from host immune forces and antibiotics,at least their viable
intravacuolar or hyperparasitic variants.
The postural/postprandial expectoration of infected dense mucus,the
alternate per oral/per rectal metronidazole use,antigenically poor
lactovegetable diet and dextro-ventral lying position may facilitate
TE from digestive and respiratory tracts.
Ventral lying alleviates bronchial clearence and immune function of
Payer'patches during digestion of infected food.Rightside lying
enables gravitational flow of liver/pancreas secretions and prevents
duodeno-pancreatic T ascension to proximity of endo/exo-crine cells,
as this author recently suggested /VIIth Human Antibodies Internatio-
nal Conf Edinburgh 1999/.
 The infection of any organ with these immunoerosive agents and
genetically determined antiparasitic host reactions implicate great
clinical importance of careful testing of proposed CF therapy model,
particularly by patients affected by respiratory trichomoniasis.


Presented on XIIIth International Cystic Fibrosis Congress, 4-8 June
2000 in Stockholm,Sweden.ABSTRACT 381,P.:176